Immunotherapy vs Chemotherapy — Which Is Better for You?

There is no single answer to whether immunotherapy or chemotherapy is "better" for you — the honest answer depends on your cancer type, stage, and biomarker results, not on which treatment sounds more advanced. In cancers where a biomarker such as PD-L1 or MSI-High/dMMR qualifies you, immunotherapy alone or combined with chemotherapy is often the guideline-preferred first option under NCCN and ASCO recommendations. In many other cancers, chemotherapy remains the standard first choice.

Most cancer patients in India are not automatically eligible for immunotherapy alone — eligibility depends on a specific biomarker test result and cancer type, not on preference or how a treatment is marketed. See who is eligible for immunotherapy — and who is not for the fuller eligibility picture before assuming either option is available to you.

"Which works better" also is not the same question as "does it work at all." For an honest look at how often immunotherapy actually helps, and for whom, see our companion page on honest immunotherapy response rates.

Chemotherapy's side effects are common and predictable: hair loss, low blood counts, nausea, and fatigue appear in a dose-related pattern your oncology team can generally anticipate and plan around. Most patients experience at least some of these effects during active treatment, and they typically ease once treatment ends.

Immunotherapy causes fewer side effects overall in most people, but the pattern is less predictable. Because it works by activating your immune system rather than killing cells directly, it can trigger immune-related adverse events (irAEs) — inflammation that can affect almost any organ, from the gut and liver to the thyroid, lungs, or skin. irAEs can appear early, late in a treatment course, or even months after stopping.

Neither pattern is automatically "worse" in every case — it depends on which specific side effects you experience, how quickly they're caught, and how well they respond to treatments such as steroids.

1. 1

   Confirm the exact diagnosis and stage

   The cancer's type, subtype, and stage narrow the field of guideline-approved options long before biomarkers are even considered.

2. 2

   Biomarker testing, where relevant

   Results such as PD-L1 expression, MSI-High/dMMR, or TMB can, on their own, rule immunotherapy in or out for a given case.

3. 3

   Overall fitness and organ function

   Heart, lung, liver, and kidney function, along with your general strength, affect how well you're likely to tolerate either treatment.

4. 4

   Tumour board review

   Multiple oncologists — medical, surgical, and radiation — review the combined evidence together, rather than one doctor deciding alone.

5. 5

   The plan — and the honest alternative

   Sometimes the answer is one treatment, sometimes both together. For a smaller group of patients, best supportive care alone is discussed as a genuine option too.

Chemotherapy is usually given as an intravenous infusion in cycles, often every two to three weeks, sometimes with pre-medications to reduce nausea beforehand. Immunotherapy is also given as an intravenous infusion, typically every two to six weeks depending on the specific regimen, generally with a simpler pre-medication routine and a shorter infusion time per visit. Both are administered as day-care procedures at CION centres — you go home the same day for either treatment.

Neither treatment currently has a home or oral self-administered equivalent in routine practice for most cancers — both require supervised infusion visits, which is part of why the schedule itself is a real factor in choosing between them.

For some patients — particularly those who are frail, have widespread disease, or for whom both treatments would carry more burden than benefit — best supportive (palliative) care alone is a genuine, guideline-recognised path, not a failure to treat or "giving up." It focuses on comfort, symptom control, and quality of life.

This is not a decision this page, or any search result, can make for you. It is a conversation for your oncology team, ideally alongside your family, once your complete picture — diagnosis, stage, biomarkers, and your own priorities — is on the table.

CION's tumour board reviews cancer type, stage, and biomarker results together for every patient before recommending immunotherapy, chemotherapy, or a combination of the two — decisions for healing, not billing. For the fuller picture of how immunotherapy is used and monitored at CION, see Immunotherapy at CION Cancer Clinics.

This page compares immunotherapy and chemotherapy in general terms to support your conversation with an oncologist — it does not recommend one treatment over another for your specific case. Response patterns and side-effect descriptions here are general, guideline-sourced information (NCCN, ASCO), not predictions for any individual. Only your treating oncology team, reviewing your complete case, can advise on eligibility and treatment choice.

Thousands have weighed this same choice with our team

Comparing two treatment paths from search results is not the same as reviewing your actual case with an oncologist. Take the first step today — our team walks this part of the journey with you.